Top

Published in:

01-11-2020 | Tamoxifen | Original Paper

Novel Murine Models of Cerebral Cavernous Malformations

Authors: Matthew R. Detter, Robert Shenkar, Christian R. Benavides, Catherine A. Neilson, Thomas Moore, Rhonda Lightle, Nicholas Hobson, Le Shen, Ying Cao, Romuald Girard, Dongdong Zhang, Erin Griffin, Carol J. Gallione, Issam A. Awad, Douglas A. Marchuk

Published in: Angiogenesis | Issue 4/2020

Abstract

Cerebral cavernous malformations (CCMs) are ectatic capillary-venous malformations that develop in approximately 0.5% of the population. Patients with CCMs may develop headaches, focal neurologic deficits, seizures, and hemorrhages. While symptomatic CCMs, depending upon the anatomic location, can be surgically removed, there is currently no pharmaceutical therapy to treat CCMs. Several mouse models have been developed to better understand CCM pathogenesis and test therapeutics. The most common mouse models induce a large CCM burden that is anatomically restricted to the cerebellum and contributes to lethality in the early days of life. These inducible models thus have a relatively short period for drug administration. We developed an inducible CCM3 mouse model that develops CCMs after weaning and provides a longer period for potential therapeutic intervention. Using this new model, three recently proposed CCM therapies, fasudil, tempol, vitamin D₃, and a combination of the three drugs, failed to substantially reduce CCM formation when treatment was administered for 5 weeks, from postnatal day 21 (P21) to P56. We next restricted Ccm3 deletion to the brain vasculature and provided greater time (121 days) for CCMs to develop chronic hemorrhage, recapitulating the human lesions. We also developed the first model of acute CCM hemorrhage by injecting mice harboring CCMs with lipopolysaccharide. These efficient models will enable future drug studies to more precisely target clinically relevant features of CCM disease: CCM formation, chronic hemorrhage, and acute hemorrhage.

Available only for authorised users

Rigamonti D, Hadley MN, Drayer BP, Johnson PC, Hoenig-Rigamonti K, Knight JT et al (1988) Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 319(6):343–347. https://doi.org/10.1056/nejm198808113190605CrossRefPubMed

Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823CrossRef

Sahoo T, Johnson EW, Thomas JW, Kuehl PM, Jones TL, Dokken CG et al (1999) Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet 8(12):2325–2333CrossRef

Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, Cecillon M et al (1999) Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 23(2):189–193. https://doi.org/10.1038/13815CrossRefPubMed

Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T et al (2003) Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 73(6):1459–1464. https://doi.org/10.1086/380314CrossRefPubMedPubMedCentral

Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A et al (2004) Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet 74(2):326–337. https://doi.org/10.1086/381718CrossRefPubMedPubMedCentral

Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M et al (2005) Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 76(1):42–51. https://doi.org/10.1086/426952CrossRefPubMed

Gault J, Shenkar R, Recksiek P, Awad IA (2005) Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke 36(4):872–874. https://doi.org/10.1161/01.STR.0000157586.20479.fdCrossRefPubMed

Gault J, Awad IA, Recksiek P, Shenkar R, Breeze R, Handler M et al (2009) Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery 65(1):138–144; discussion 44–45. https://doi.org/10.1227/01.neu.0000348049.81121.c1

10.

Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA (2009) Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 18(5):919–930. https://doi.org/10.1093/hmg/ddn430CrossRefPubMed

11.

McDonald DA, Shi C, Shenkar R, Gallione CJ, Akers AL, Li S et al (2014) Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet 23(16):4357–4370. https://doi.org/10.1093/hmg/ddu153CrossRefPubMedPubMedCentral

12.

Zabramski JM, Wascher TM, Spetzler RF, Johnson B, Golfinos J, Drayer BP et al (1994) The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg 80(3):422–432. https://doi.org/10.3171/jns.1994.80.3.0422CrossRefPubMed

13.

Horne MA, Flemming KD, Su IC, Stapf C, Jeon JP, Li D et al (2016) Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol 15(2):166–173. https://doi.org/10.1016/s1474-4422(15)00303-8CrossRefPubMedPubMedCentral

14.

Al-Shahi Salman R, Hall JM, Horne MA, Moultrie F, Josephson CB, Bhattacharya JJ et al (2012) Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol 11(3):217–224. https://doi.org/10.1016/s1474-4422(12)70004-2CrossRefPubMed

15.

Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J et al (2009) The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 15(2):177–184. https://doi.org/10.1038/nm.1911CrossRefPubMedPubMedCentral

16.

Crose LE, Hilder TL, Sciaky N, Johnson GL (2009) Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. J Biol Chem 284(20):13301–13305. https://doi.org/10.1074/jbc.C900009200CrossRefPubMedPubMedCentral

17.

Stockton RA, Shenkar R, Awad IA, Ginsberg MH (2010) Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med 207(4):881–896. https://doi.org/10.1084/jem.20091258CrossRefPubMedPubMedCentral

18.

Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S et al (2010) Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem 285(16):11760–11764. https://doi.org/10.1074/jbc.C109.097220CrossRefPubMedPubMedCentral

19.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R et al (2016) Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature 532(7597):122–126. https://doi.org/10.1038/nature17178CrossRefPubMedPubMedCentral

20.

Cuttano R, Rudini N, Bravi L, Corada M, Giampietro C, Papa E et al (2015) KLF4 is a key determinant in the development and progression of cerebral cavernous malformations. EMBO Mol Med 8(1):6–24. https://doi.org/10.15252/emmm.201505433CrossRefPubMedCentral

21.

Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N et al (2017) Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature 545(7654):305–310. https://doi.org/10.1038/nature22075CrossRefPubMedPubMedCentral

22.

Faurobert E, Rome C, Lisowska J, Manet-Dupe S, Boulday G, Malbouyres M et al (2013) CCM1-ICAP-1 complex controls beta1 integrin-dependent endothelial contractility and fibronectin remodeling. J Cell Biol 202(3):545–561. https://doi.org/10.1083/jcb.201303044CrossRefPubMedPubMedCentral

23.

Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA (2002) KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet 11(4):389–396. https://doi.org/10.1093/hmg/11.4.389CrossRefPubMed

24.

Wustehube J, Bartol A, Liebler SS, Brutsch R, Zhu Y, Felbor U et al (2010) Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci USA 107(28):12640–12645. https://doi.org/10.1073/pnas.1000132107CrossRefPubMed

25.

Zhou HJ, Qin L, Zhang H, Tang W, Ji W, He Y et al (2016) Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation. Nat Med 22(9):1033–1042. https://doi.org/10.1038/nm.4169CrossRef

26.

Lopez-Ramirez MA, Pham A, Girard R, Wyseure T, Hale P, Yamashita A et al (2019) Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood 133(3):193–204. https://doi.org/10.1182/blood-2018-06-856062CrossRefPubMedPubMedCentral

27.

Goitre L, Balzac F, Degani S, Degan P, Marchi S, Pinton P et al (2010) KRIT1 regulates the homeostasis of intracellular reactive oxygen species. PLoS ONE 5(7):e11786. https://doi.org/10.1371/journal.pone.0011786CrossRefPubMedPubMedCentral

28.

Marchi S, Corricelli M, Trapani E, Bravi L, Pittaro A, Delle Monache S et al (2015) Defective autophagy is a key feature of cerebral cavernous malformations. EMBO Mol Med 7(11):1403–1417. https://doi.org/10.15252/emmm.201505316CrossRefPubMedPubMedCentral

29.

Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M et al (2013) EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature 498(7455):492–496. https://doi.org/10.1038/nature12207CrossRefPubMed

30.

McDonald DA, Shi C, Shenkar R, Stockton RA, Liu F, Ginsberg MH et al (2012) Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke 43(2):571–574. https://doi.org/10.1161/strokeaha.111.625467CrossRefPubMed

31.

Bravi L, Rudini N, Cuttano R, Giampietro C, Maddaluno L, Ferrarini L et al (2015) Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice. Proc Natl Acad Sci USA 112(27):8421–8426. https://doi.org/10.1073/pnas.1501352112CrossRefPubMed

32.

Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J et al (2015) Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation 131(3):289–299. https://doi.org/10.1161/circulationaha.114.010403CrossRefPubMed

33.

Nishimura S, Mishra-Gorur K, Park J, Surovtseva YV, Sebti SM, Levchenko A et al (2017) Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proc Natl Acad Sci USA 114(21):5503–5508. https://doi.org/10.1073/pnas.1702942114CrossRefPubMed

34.

Otten C, Knox J, Boulday G, Eymery M, Haniszewski M, Neuenschwander M et al (2018) Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations. EMBO Mol Med. https://doi.org/10.15252/emmm.201809155CrossRefPubMedPubMedCentral

35.

Lopez-Ramirez MA, Fonseca G, Zeineddine HA, Girard R, Moore T, Pham A et al (2017) Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. https://doi.org/10.1084/jem.20171178CrossRefPubMedPubMedCentral

36.

Zabramski JM, Kalani MYS, Filippidis AS, Spetzler RF (2016) Propranolol treatment of cavernous malformations with symptomatic hemorrhage. World Neurosurg 88:631–639. https://doi.org/10.1016/j.wneu.2015.11.003CrossRefPubMed

37.

Reinhard M, Schuchardt F, Meckel S, Heinz J, Felbor U, Sure U et al (2016) Propranolol stops progressive multiple cerebral cavernoma in an adult patient. J Neurol Sci 367:15–17. https://doi.org/10.1016/j.jns.2016.04.053CrossRefPubMed

38.

Choi JP, Wang R, Yang X, Wang X, Wang L, Ting KK et al (2018) Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations. Sci Adv. 4(11):eaau0731. https://doi.org/10.1126/sciadv.aau0731CrossRefPubMedPubMedCentral

39.

McKerracher L, Shenkar R, Abbinanti M, Cao Y, Peiper A, Liao JK et al (2019) A brain-targeted orally available ROCK2 inhibitor benefits mild and aggressive cavernous angioma disease. Transl Stroke Res. https://doi.org/10.1007/s12975-019-00725-8CrossRefPubMed

40.

DiStefano PV, Glading AJ (2020) VEGF signalling enhances lesion burden in KRIT1 deficient mice. J Cell Mol Med 24(1):632–639. https://doi.org/10.1111/jcmm.14773CrossRefPubMed

41.

Lant B, Yu B, Goudreault M, Holmyard D, Knight JD, Xu P et al (2015) CCM-3/STRIPAK promotes seamless tube extension through endocytic recycling. Nat Commun 6:6449. https://doi.org/10.1038/ncomms7449CrossRefPubMed

42.

Mably JD, Chuang LP, Serluca FC, Mohideen MA, Chen JN, Fishman MC (2006) santa and valentine pattern concentric growth of cardiac myocardium in the zebrafish. Development 133(16):3139–3146. https://doi.org/10.1242/dev.02469CrossRefPubMed

43.

Hogan BM, Bussmann J, Wolburg H, Schulte-Merker S (2008) ccm1 cell autonomously regulates endothelial cellular morphogenesis and vascular tubulogenesis in zebrafish. Hum Mol Genet 17(16):2424–2432. https://doi.org/10.1093/hmg/ddn142CrossRefPubMed

44.

Voss K, Stahl S, Hogan BM, Reinders J, Schleider E, Schulte-Merker S et al (2009) Functional analyses of human and zebrafish 18-amino acid in-frame deletion pave the way for domain mapping of the cerebral cavernous malformation 3 protein. Hum Mutat 30(6):1003–1011. https://doi.org/10.1002/humu.20996CrossRefPubMed

45.

Kleaveland B, Zheng X, Liu JJ, Blum Y, Tung JJ, Zou Z et al (2009) Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med 15(2):169–176. https://doi.org/10.1038/nm.1918CrossRefPubMedPubMedCentral

46.

Yoruk B, Gillers BS, Chi NC, Scott IC (2012) Ccm3 functions in a manner distinct from Ccm1 and Ccm2 in a zebrafish model of CCM vascular disease. Dev Biol 362(2):121–131. https://doi.org/10.1016/j.ydbio.2011.12.006CrossRefPubMed

47.

Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY (2004) Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development 131(6):1437–1448. https://doi.org/10.1242/dev.01036CrossRefPubMed

48.

Plummer NW, Squire TL, Srinivasan S, Huang E, Zawistowski JS, Matsunami H et al (2006) Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm Genome 17(2):119–128. https://doi.org/10.1007/s00335-005-0098-8CrossRefPubMed

49.

Boulday G, Blecon A, Petit N, Chareyre F, Garcia LA, Niwa-Kawakita M et al (2009) Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Models Mech 2(3–4):168–177. https://doi.org/10.1242/dmm.001263CrossRef

50.

He Y, Zhang H, Yu L, Gunel M, Boggon TJ, Chen H et al (2010) Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal 3(116):ra26. https://doi.org/10.1126/scisignal.2000722CrossRefPubMedPubMedCentral

51.

McDonald DA, Shenkar R, Shi C, Stockton RA, Akers AL, Kucherlapati MH et al (2011) A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet 20(2):211–222. https://doi.org/10.1093/hmg/ddq433CrossRefPubMed

52.

Chan AC, Drakos SG, Ruiz OE, Smith AC, Gibson CC, Ling J et al (2011) Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice. J Clin Invest 121(5):1871–1881. https://doi.org/10.1172/jci44393CrossRefPubMedPubMedCentral

53.

Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA (2004) Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol 165(5):1509–1518. https://doi.org/10.1016/s0002-9440(10)63409-8CrossRefPubMedPubMedCentral

54.

Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y et al (2017) RhoA Kinase inhibition with fasudil versus simvastatin in murine models of cerebral cavernous malformations. Stroke 48(1):187–194. https://doi.org/10.1161/strokeaha.116.015013CrossRefPubMed

55.

Shenkar R, Peiper A, Pardo H, Moore T, Lightle R, Girard R et al (2019) Rho kinase inhibition blunts lesion development and hemorrhage in murine models of aggressive Pdcd10/Ccm3 disease. Stroke 50(3):738–744. https://doi.org/10.1161/strokeaha.118.024058CrossRefPubMedPubMedCentral

56.

Louvi A, Chen L, Two AM, Zhang H, Min W, Gunel M (2011) Loss of cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular pathology. Proc Natl Acad Sci USA 108(9):3737–3742. https://doi.org/10.1073/pnas.1012617108CrossRefPubMed

57.

Zheng X, Xu C, Smith AO, Stratman AN, Zou Z, Kleaveland B et al (2012) Dynamic regulation of the cerebral cavernous malformation pathway controls vascular stability and growth. Dev Cell 23(2):342–355. https://doi.org/10.1016/j.devcel.2012.06.004CrossRefPubMedPubMedCentral

58.

Mleynek TM, Chan AC, Redd M, Gibson CC, Davis CT, Shi DS et al (2014) Lack of CCM1 induces hypersprouting and impairs response to flow. Hum Mol Genet 23(23):6223–6234. https://doi.org/10.1093/hmg/ddu342CrossRefPubMedPubMedCentral

59.

Zeineddine HA, Girard R, Saadat L, Shen L, Lightle R, Moore T et al (2019) Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest 99(3):319–330. https://doi.org/10.1038/s41374-018-0030-yCrossRefPubMed

60.

Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M (2008) Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis 46(2):74–80. https://doi.org/10.1002/dvg.20367CrossRefPubMed

61.

Ridder DA, Lang MF, Salinin S, Roderer JP, Struss M, Maser-Gluth C et al (2011) TAK1 in brain endothelial cells mediates fever and lethargy. J Exp Med 208(13):2615–2623. https://doi.org/10.1084/jem.20110398CrossRefPubMedPubMedCentral

62.

Boulday G, Rudini N, Maddaluno L, Blécon A, Arnould M, Gaudric A et al (2011) Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice. J Exp Med 208(9):1835–1847. https://doi.org/10.1084/jem.20110571CrossRefPubMedPubMedCentral

63.

Robertson PL, Du Bois M, Bowman PD, Goldstein GW (1985) Angiogenesis in developing rat brain: an in vivo and in vitro study. Brain Res 355(2):219–223. https://doi.org/10.1016/0165-3806(85)90044-6CrossRefPubMed

64.

Plate KH (1999) Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 58(4):313–320. https://doi.org/10.1097/00005072-199904000-00001CrossRefPubMed

65.

Acker T, Beck H, Plate KH (2001) Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev 108(1):45–57. https://doi.org/10.1016/S0925-4773(01)00471-3CrossRefPubMed

66.

Shi C, Shenkar R, Du H, Duckworth E, Raja H, Batjer HH et al (2009) Immune response in human cerebral cavernous malformations. Stroke 40(5):1659–1665. https://doi.org/10.1161/strokeaha.108.538769CrossRefPubMedPubMedCentral

67.

Shi C, Shenkar R, Zeineddine HA, Girard R, Fam MD, Austin C et al (2016) B-cell depletion reduces the maturation of cerebral cavernous malformations in murine models. J Neuroimmune Pharmacol 11(2):369–377. https://doi.org/10.1007/s11481-016-9670-0CrossRefPubMedPubMedCentral

68.

Girard R, Zeineddine HA, Fam MD, Mayampurath A, Cao Y, Shi C et al (2017) Plasma biomarkers of inflammation reflect seizures and hemorrhagic activity of cerebral cavernous malformations. Transl Stroke Res 9(1):34–43. https://doi.org/10.1007/s12975-017-0561-3CrossRefPubMedPubMedCentral

69.

Denier C, Labauge P, Bergametti F, Marchelli F, Riant F, Arnoult M et al (2006) Genotype–phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 60(5):550–556. https://doi.org/10.1002/ana.20947CrossRefPubMed

70.

Riant F, Bergametti F, Fournier HD, Chapon F, Michalak-Provost S, Cecillon M et al (2013) CCM3 mutations are associated with early-onset cerebral hemorrhage and multiple meningiomas. Mol Syndromol 4(4):165–172. https://doi.org/10.1159/000350042CrossRefPubMedPubMedCentral

71.

Shenkar R, Shi C, Rebeiz T, Stockton RA, McDonald DA, Mikati AG et al (2015) Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med 17(3):188–196. https://doi.org/10.1038/gim.2014.97CrossRefPubMed

72.

Cardoso C, Arnould M, De Luca C, Otten C, Abdelilah-Seyfried S, Heredia A et al (2020) Novel chronic mouse model of cerebral cavernous malformations. Stroke. https://doi.org/10.1161/strokeaha.119.027207CrossRefPubMed

73.

Koskimaki J, Zhang D, Carrion-Penagos J, Girard R, Piedad K, Polster SP et al (2020) Symptomatic brain hemorrhages from cavernous angioma after botulinum toxin injections, a role of TLR/MEKK3 mechanism? Case report and review of the literature. World Neurosurg 136:7–11. https://doi.org/10.1016/j.wneu.2019.12.172CrossRefPubMed

Title: Novel Murine Models of Cerebral Cavernous Malformations
Authors: Matthew R. Detter
Robert Shenkar
Christian R. Benavides
Catherine A. Neilson
Thomas Moore
Rhonda Lightle
Nicholas Hobson
Le Shen
Ying Cao
Romuald Girard
Dongdong Zhang
Erin Griffin
Carol J. Gallione
Issam A. Awad
Douglas A. Marchuk
Publication date: 01-11-2020
Publisher: Springer Netherlands
Keyword: Tamoxifen
Published in: Angiogenesis / Issue 4/2020
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-020-09736-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Novel Murine Models of Cerebral Cavernous Malformations

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation

Embryonic circulating endothelial progenitor cells

Leopold Auerbach’s achievements in the field of vascular system

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

Tumor-derived exosomes promote angiogenesis via adenosine A2B receptor signaling

Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page